about
E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomesThe progress of angiogenic factors in the development of leukemiasHypoxia and metabolic adaptation of cancer cellsEpigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor HypoxiaProgress toward overcoming hypoxia-induced resistance to solid tumor therapyIntertwined regulation of angiogenesis and immunity by myeloid cellsImaging tumor hypoxia to advance radiation oncologyHypoxia-inducible factors in physiology and medicineEmerging roles for HMGB1 protein in immunity, inflammation, and cancerSpatial Structure and pH-dependent Conformational Diversity of Dimeric Transmembrane Domain of the Receptor Tyrosine Kinase EphA1Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective CandidatesVascular permeability--the essentialsRole of cancer microenvironment in metastasis: focus on colon cancermiR-190 Enhances HIF-Dependent Responses to Hypoxia in Drosophila by Inhibiting the Prolyl-4-hydroxylase FatigaExosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor developmentHypoxia-Targeted Drug Q6 Induces G2-M Arrest and Apoptosis via Poisoning Topoisomerase II under HypoxiaDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsCochlear pericyte responses to acoustic trauma and the involvement of hypoxia-inducible factor-1alpha and vascular endothelial growth factor.Host endothelial S1PR1 regulation of vascular permeability modulates tumor growthClinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer.Circulating cell death products predict clinical outcome of colorectal cancer patientsRegulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration.Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer.Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.RNA-binding proteins implicated in the hypoxic response.EP300 contributes to high-altitude adaptation in Tibetans by regulating nitric oxide production.Myricetin inhibits UVB-induced angiogenesis by regulating PI-3 kinase in vivo.Targeting protein-protein interactions for therapeutic intervention: a challenge for the future.Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT).Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia.Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway.Aryl hydrocarbon nuclear translocator (hypoxia inducible factor 1beta) activity is required more during early than late tumor growthWhole brain radiation-induced impairments in learning and memory are time-sensitive and reversible by systemic hypoxia.MicroRNA regulation network in colorectal cancer metastasisAngiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.The tumor microenvironment in colorectal carcinogenesis.Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells.
P2860
Q24296966-0445012E-28AB-453C-9593-F57C6F956692Q24604279-AD1737FB-A617-49BE-9457-939DC10EBC0AQ26753835-43F018B1-61B4-40C0-8265-71F0BC808093Q26774856-94F4F554-E5A5-4389-89C4-145BFAA6AC81Q26783014-8A766675-66F0-4FEE-A57F-02346D3DD6DDQ26796405-6B906701-A2BB-464E-9195-2F402EDB2907Q26830418-01086004-A44E-4146-ACDD-9E7C25A16EBFQ27007862-385ADC57-BA98-4701-A3B3-6BBBDE13BB07Q27013770-3AFAC979-FA80-4C86-A616-2EBA970160F6Q27015835-FE2FBAFC-C75C-4F37-8E33-37F518BC814EQ27651810-2E34FC13-337F-4A41-B8E7-2F6A462F8994Q28071510-876D9D75-BA74-4281-9D84-07BCB1F61F64Q28085112-3702114F-8BC6-412A-A461-33913F56958FQ28239062-719803ED-FB68-4C6B-AD94-07F16E6EE9B5Q28395196-243D06EC-2A29-4B3F-8A5E-19E86A4611B6Q28397739-52087382-88CE-4388-B633-69517605B6B0Q28551450-83BCCC4B-BF5A-4817-9BE0-E9B2194750E2Q29615944-4B156BB9-4A12-4A57-9AA9-1088191F4E12Q30485540-3763B9D4-E70E-4985-8F4B-C984E36DB937Q30582575-EDE8C770-927B-4D0A-B9FA-D38600D91C51Q33331462-4EFE38F2-C98E-4C5E-B1FC-3574D0D97CE9Q33420106-A7500E14-9465-4B4A-B9D4-43DE1E743D4FQ33515259-85BA41F2-5C63-4037-8E40-E2C5E3327F5BQ33539996-98DF1C84-C2CD-45F8-9FEE-2FC0EA276966Q33557565-F4650584-7B01-431E-AA3D-79A6A852E338Q33703426-A4347663-B327-4768-A8EC-E2753F3C87ABQ33766952-5E08D97B-6082-4AE5-B981-9DF1FD77C21BQ33829163-9D164B03-556A-4B2C-B060-8760AABF5F72Q33852396-5CDC6AC0-1F24-4D7D-A5F4-C2BDC6D9C774Q33862570-3F4C6FC3-C86B-4976-834E-61CB5D069FF6Q33933054-F6F56F35-D744-43D8-8FC9-155DBB73D4ACQ33946966-75AC8651-25F4-4470-A122-F030A63AEE0DQ34033506-CD6CFF90-233E-4B28-B36D-970D877D2ACAQ34124534-C7FC9FA6-FBA2-4755-9821-9B2918BCB490Q34141823-1EF86928-8F43-4E20-A067-3E739EFCC7B0Q34161573-9700B666-949E-4520-8D1D-D4775D2A47B5Q34238619-829689F3-4EF4-4311-81AE-2EFA151A0614Q34343645-7F59FF92-6181-4CC3-BF5A-8CE0D97BA6BBQ34382527-FBCB99B3-189F-4175-AF2A-7CC2C32DA9CBQ34408337-1BC1F958-1AEE-4850-A430-AD0253211B50
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Hypoxia: a key regulator of angiogenesis in cancer.
@en
type
label
Hypoxia: a key regulator of angiogenesis in cancer.
@en
prefLabel
Hypoxia: a key regulator of angiogenesis in cancer.
@en
P1476
Hypoxia: a key regulator of angiogenesis in cancer.
@en
P2093
Debbie Liao
Randall S Johnson
P2888
P304
P356
10.1007/S10555-007-9066-Y
P577
2007-06-01T00:00:00Z